Melanocortin Pathways: Skin Pigment and Sexual Arousal
Melanotan II and Sexual Function
5 Receptors one family
Five melanocortin receptors control functions from skin color to appetite to sexual desire, all activated by peptides cleaved from a single precursor protein called POMC.
Van der Ploeg et al., PNAS, 2002
Van der Ploeg et al., PNAS, 2002
View as imageA peptide designed to tan skin caused spontaneous erections in clinical volunteers. That accidental finding, documented in the Melanotan II discovery story, revealed something fundamental about human biology: the same signaling family that controls skin color also drives sexual desire. The melanocortin pathway is the molecular link between these seemingly unrelated functions. Five receptors, one precursor protein, and a set of peptide fragments connect melanocytes in your skin to arousal circuits deep in the hypothalamus. This article maps the biology behind that connection, from the gene that produces melanocortin peptides to the receptor subtypes that sort their effects across the body.
Key Takeaways
- All melanocortin peptides originate from one precursor protein called POMC, which is cleaved into alpha-MSH, beta-MSH, gamma-MSH, and ACTH in different tissues (Van der Ploeg et al., PNAS, 2002)
- MC1R activation on melanocytes drives eumelanin synthesis and skin darkening, while MC4R activation in the hypothalamus initiates sexual arousal through descending spinal pathways (Wessells et al., Peptides, 2005)
- Melanotan II caused erections in 17 of 20 men without sexual stimulation because it activates both MC1R and MC4R non-selectively (Wessells et al., International Journal of Impotence Research, 2000)
- MC4R knockout mice show normal pigmentation but impaired sexual behavior, confirming that sexual function depends specifically on MC4R, not MC1R (Van der Ploeg et al., PNAS, 2002)
- Bremelanotide (PT-141), derived from Melanotan II, targets MC4R in the brain and became the first centrally-acting peptide approved for hypoactive sexual desire disorder (Dhillon et al., Drugs, 2019)
- The melanocortin system also regulates appetite, inflammation, and adrenal function through MC2R, MC3R, and MC5R, making it one of the most functionally diverse peptide families in human biology (Molinoff et al., Annals of the New York Academy of Sciences, 2003)
POMC: the master precursor
The melanocortin story begins with a single gene. Pro-opiomelanocortin (POMC) encodes a 241-amino-acid precursor protein that is cleaved into at least 10 biologically active peptides depending on the tissue where it is processed. In the anterior pituitary, POMC produces ACTH (adrenocorticotropic hormone), which stimulates cortisol release from the adrenal glands. In the intermediate lobe of the pituitary and in hypothalamic neurons, POMC is further processed into alpha-MSH, beta-MSH, gamma-MSH, and beta-endorphin.[1]
This tissue-specific cleavage is the first critical detail. The same gene produces different active peptides in different locations. Alpha-MSH, the peptide most relevant to both pigmentation and sexual function, is a 13-amino-acid fragment that activates melanocortin receptors with varying affinities. It circulates at low concentrations in blood but reaches high local concentrations in skin (produced by keratinocytes in response to UV radiation) and in the hypothalamus (produced by POMC neurons in the arcuate nucleus).[2]
The same precursor also produces beta-endorphin, an endogenous opioid. This means POMC-expressing neurons simultaneously release peptides that affect pain perception, mood, appetite, pigmentation, adrenal function, and sexual behavior. The melanocortin system is not a narrow signaling pathway; it is a branching network where one gene influences multiple physiological systems through receptor-specific sorting.
The five melanocortin receptors
The melanocortin receptors (MC1R through MC5R) are all G protein-coupled receptors that signal primarily through cyclic AMP (cAMP). They share structural similarities but differ in their tissue distribution and ligand preferences, which is how one family of peptides produces such varied effects.[3]
MC1R is expressed on melanocytes in the skin and hair follicles. When alpha-MSH binds MC1R, it activates adenylyl cyclase, raises intracellular cAMP, and stimulates the transcription factor MITF (microphthalmia-associated transcription factor). MITF drives the expression of tyrosinase and other enzymes required for eumelanin synthesis, the dark brown-black pigment that provides UV protection. Loss-of-function MC1R variants are the primary genetic determinant of red hair and fair skin in humans, and they substantially increase melanoma risk.[4]
MC2R is the ACTH receptor, found almost exclusively on adrenal cortical cells. It does not bind alpha-MSH with meaningful affinity and plays no direct role in pigmentation or sexual function. Its relevance here is contextual: MC2R activation by ACTH is part of the stress response, and stress profoundly modulates both skin pigmentation (through cortisol effects on melanocytes) and sexual function (through cortisol suppression of gonadal hormones).
MC3R is expressed in the hypothalamus, limbic system, and peripheral tissues including the gut and immune cells. It participates in energy homeostasis and feeding behavior. MC3R also plays a role in the timing of sexual maturation, and MC3R-null mice show altered reproductive timing.[5]
MC4R is the receptor most directly responsible for melanocortin-driven sexual arousal. It is expressed in the paraventricular nucleus and medial preoptic area of the hypothalamus, brain regions that regulate sexual motivation and erectile function. MC4R is also a major regulator of appetite and energy expenditure, which is why MC4R loss-of-function mutations are the most common monogenic cause of severe obesity in humans.[3]
MC5R is the least studied. It is widely distributed in exocrine glands and appears to regulate sebaceous gland secretion. MC5R-deficient mice produce less sebum.
The functional sorting is clear: MC1R handles pigmentation in the periphery, MC4R handles sexual arousal and appetite in the brain, and they are activated by the same ligand, alpha-MSH, produced from the same precursor, POMC. This is why a non-selective melanocortin agonist like Melanotan II simultaneously tans skin and triggers erections.
MC1R and pigmentation: the skin side
When UV radiation hits keratinocytes in the epidermis, it triggers POMC expression and alpha-MSH release. Alpha-MSH then binds MC1R on neighboring melanocytes, stimulating a signaling cascade that shifts melanin production from pheomelanin (yellow-red, photoprotectively weak) toward eumelanin (brown-black, photoprotectively strong). This is the tanning response.[4]
MC1R signaling does more than darken skin. It activates DNA repair pathways in melanocytes, reduces oxidative stress, and suppresses inflammatory signaling through NF-kB inhibition. Loss-of-function MC1R variants (the R151C, R160W, and D294H alleles common in people of Northern European descent) are associated not only with red hair and fair skin but with increased melanoma risk independent of skin color. The receptor's role extends beyond pigment production into cellular damage control.
This is the pathway Melanotan II was designed to activate. University of Arizona researchers, including Victor Hruby and Mac Hadley, synthesized MT-II as a potent, stable analog of alpha-MSH that could resist enzymatic degradation and activate MC1R to produce tanning without UV exposure. The goal was a injectable photoprotective agent. In early self-experimentation and subsequent clinical studies, it worked: subjects developed measurable increases in skin melanin density.[6]
But MT-II does not stop at MC1R. As a non-selective agonist with sub-nanomolar affinity for MC1R, MC3R, MC4R, and MC5R, it simultaneously activates receptors throughout the central nervous system. The pigmentation effect and the sexual effect are pharmacologically inseparable in this molecule.
MC4R and sexual arousal: the brain side
The evidence that MC4R specifically mediates melanocortin sexual effects comes from Van der Ploeg and colleagues at Merck Research Laboratories, who published a landmark 2002 paper in PNAS. Using MC4R-knockout mice, they demonstrated that a selective MC4R agonist increased erectile activity in wild-type animals but had zero effect in mice lacking the MC4R gene. Copulatory behavior was enhanced by MC4R agonist administration in normal mice but diminished in MC4R-null animals. The receptor was found expressed in rat and human penile tissue, spinal cord, hypothalamus, brainstem, and pelvic ganglia.[3]
A critical observation: intracavernosal injection of melanocortin agonists (directly into penile tissue) produced no erectile effect. The pro-erectile activity required central nervous system activation. Both the melanocortin receptor antagonist SHU 9119 and the nitric oxide synthase inhibitor L-NAME blocked the effects of MT-II, indicating that central MC4R activation produces erections by triggering nitric oxide release through descending spinal pathways. The signal originates in the brain and travels to the genitals through autonomic nerves, not through direct action on penile blood vessels.[5]
Wessells, Blevins, and Vanderah (2005) mapped this circuitry in greater detail. POMC neurons in the arcuate nucleus of the hypothalamus project to the paraventricular nucleus (PVN), where MC4R is densely expressed. PVN neurons containing oxytocin project to the lumbosacral spinal cord, specifically to autonomic preganglionic neurons that control penile erection through the pelvic nerve. Alpha-MSH or synthetic agonists activate this cascade: MC4R in the PVN activates oxytocinergic neurons, which activate spinal autonomic neurons, which release nitric oxide in the corpus cavernosum.[5]
This pathway explains several observations. It explains why MC4R agonists cause erections without sexual stimulation (they activate the pathway upstream of conscious arousal). It explains why PDE5 inhibitors like sildenafil work through a different mechanism (sildenafil amplifies nitric oxide signaling at the endpoint; melanocortins initiate it from the origin). And it explains why melanocortin agonists increase subjective sexual desire in addition to physical arousal: MC4R is expressed in limbic structures associated with motivation and reward, not just in motor circuits that control erection.
Why one pathway controls both functions
The question that makes this biology unusual is not "how does pigmentation work?" or "how does sexual arousal work?" but "why does the same peptide system control both?"
The answer involves evolutionary biology, though direct evidence is limited to comparative anatomy and genetic studies. POMC is an ancient gene, present in all vertebrates. In fish, amphibians, and reptiles, melanocortin signaling coordinates color change with behavioral states including territorial displays and mating. In many species, darker pigmentation signals dominance, health, or sexual maturity. Male birds with more melanin-based plumage often have higher testosterone and more aggressive mating behavior. The MC1R-pigmentation and MC4R-sexual-behavior axes may represent the vertebrate separation of functions that were once more tightly linked.
In humans, MC1R and MC4R are activated by the same endogenous ligand (alpha-MSH) but expressed in completely different tissues. The connection is biochemical, not functional: there is no evidence that darker-skinned humans have higher MC4R-mediated sexual arousal, or that MC1R loss-of-function variants (common in red-haired individuals) affect sexual function. The receptors operate independently once the shared ligand reaches its tissue-specific targets.
The pharmacological connection exists only because synthetic agonists like Melanotan II are non-selective. They flood both receptor systems simultaneously. This pharmacological accident revealed a biological relationship that endogenous signaling keeps compartmentalized.
From Melanotan II to bremelanotide: separating the signals
The clinical challenge following the MT-II discovery was clear: separate the sexual effects from the pigmentation effects (and from the nausea caused by MC3R/MC4R activation in the brainstem area postrema). Molinoff and colleagues at Palatin Technologies approached this by developing PT-141 (later named bremelanotide), a cyclic heptapeptide derived from MT-II that retained melanocortin receptor activity but was designed for intranasal administration to achieve rapid central nervous system penetration.[7]
Bremelanotide is still not perfectly selective. It activates MC1R and MC4R with similar potency. The practical separation came not from receptor selectivity but from route of administration and dosing: subcutaneous injection of 1.75 mg produces measurable MC4R activation in the brain (confirmed by neuroimaging showing hypothalamic and limbic activation) without the sustained MC1R stimulation that would produce significant tanning at that dose and frequency.[8]
Pfaus and colleagues (2007) demonstrated in preclinical models that bremelanotide activates neurons in hypothalamic regions associated with sexual motivation (the medial preoptic area and ventromedial hypothalamus) and increases c-Fos expression (a marker of neuronal activation) in these regions in female rats. The peptide selectively facilitated solicitation behaviors in female rats, the rodent equivalent of proceptive sexual behavior, without increasing non-sexual locomotor activity.[9]
For a detailed look at how bremelanotide works as a centrally-acting drug, see How Bremelanotide Works: A Central Nervous System Approach to Desire.
Clinical evidence: the pathway in practice
The RECONNECT Phase 3 trials (Kingsberg et al., 2019) tested bremelanotide 1.75 mg subcutaneous injection in 1,247 premenopausal women with hypoactive sexual desire disorder. Over 24 weeks, bremelanotide significantly increased the number of satisfying sexual events (SSEs) and reduced sexual distress scores compared to placebo. The co-primary endpoints were both met. The most common adverse events were nausea (40% vs 1% placebo), flushing (20%), and injection site reactions (13%).[10]
The nausea rate illustrates the limitation of working within the melanocortin system. Nausea is mediated by MC3R and MC4R activation in the brainstem, and it occurs through the same central mechanism that produces the desired sexual effects. Forty percent is a high rate for a chronic-use medication, and it contributed to a 12% discontinuation rate in clinical trials. The safety profile across the development program (Clayton et al., 2022) showed no serious safety signals beyond transient blood pressure increases of approximately 2-3 mmHg.[11]
Bremelanotide received FDA approval in June 2019 as Vyleesi, the first and only melanocortin receptor agonist approved for sexual dysfunction. Cipriani and colleagues (2023) reviewed the clinical program and noted that the drug's mechanism of action, activating central melanocortin pathways that regulate desire rather than genital blood flow, represents a fundamentally different pharmacological approach from any previous sexual dysfunction treatment.[12]
For the clinical evidence on bremelanotide's efficacy in women, see Vyleesi for Women: The Clinical Evidence on Hypoactive Sexual Desire. For the safety and risk profile of unregulated Melanotan II use, see The Risks of Melanotan II for Sexual Enhancement. For the broader risk picture including dermatological and cardiovascular concerns, see Melanotan II Risk Profile: Cardiovascular, Dermatological, and Beyond.
What remains unknown
The melanocortin pathway's dual control of pigmentation and sexual arousal is well-established pharmacologically, but several biological questions remain open. The precise downstream signaling events after MC4R activation in the PVN that translate into subjective desire (as opposed to reflex erection) are not fully characterized. The role of MC3R in sexual function is unclear, as MC3R-null mice show reproductive timing defects but the receptor's contribution to human sexual arousal is not established.[2]
Sex differences in melanocortin sexual pharmacology are real but poorly understood. Bremelanotide was approved only for women, despite early evidence of efficacy in men. The male and female melanocortin pathways likely share MC4R as the initiating receptor but diverge in downstream neural circuits that govern gender-specific arousal patterns.
The relationship between endogenous melanocortin tone and baseline sexual function is also unexplored in humans. Whether natural variation in POMC expression, alpha-MSH levels, or MC4R density contributes to individual differences in sexual desire has not been tested in clinical populations.
The Bottom Line
The melanocortin system connects skin pigmentation and sexual arousal through a shared biochemical origin: POMC-derived peptides activate MC1R in melanocytes and MC4R in the hypothalamus. These are functionally independent pathways that share upstream ligands and were revealed as connected only because non-selective synthetic agonists like Melanotan II activated both simultaneously. The pharmacological separation of these effects led to bremelanotide, which exploits the MC4R sexual pathway while minimizing the MC1R pigmentation pathway through dosing and route of administration.